Trial Profile
Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease (NAFLD) patients with type 2 diabetes. Randomized, open label pilot study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Tofogliflozin (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 14 Dec 2021 Status changed from recruiting to completed.
- 27 Nov 2020 Planned End Date changed from 31 Dec 2020 to 27 Nov 2020.
- 12 Jun 2020 Planned End Date changed from 31 Mar 2020 to 31 Dec 2020.